Anti-aging interventions — peptide, drug, and lifestyle options compared

The anti-aging space has the worst evidence-to-marketing ratio of any peptide category. The reasons are structural. First, "anti-aging" is not a clinical endpoint — it's a marketing umbrella over a heterogeneous mix of skin appearance, cellular senescence biomarkers, mitochondrial function, telomere length, metabolic flexibility, immune resilience, sleep architecture, and subjective vitality. Trial designs that target one of these rarely speak to the others. Second, the longevity-extension trial designs that would resolve causal claims require decades of follow-up — funding mechanisms struggle to support them, and most companies marketing "anti-aging peptides" have no path to such trials anyway. Third, the cultural pressure to look and feel younger creates large markets for anything with credible-sounding mechanism stories, even when the human evidence is thin.

This guide compares the realistic options. It is structured around a load-bearing observation: almost every intervention with strong evidence for biological-aging effects is a lifestyle intervention, not a pharmacological one. The pharmacological options with the strongest evidence (metformin, possibly rapamycin) come from the geroscience side of medicine, not from peptide research. The peptide options sit in a different position: mechanistically interesting, modestly characterized in animal models, sparsely characterized in humans, useful as adjuncts in specific contexts but not as standalone "longevity" strategies.

For peptide-curious readers expecting the encyclopedia to validate Epitalon-as-life-extension or NAD-precursor-as-anti-aging: this guide will be honest about where the evidence actually sits. The intent is harm reduction, not advocacy in either direction.

The comparison

Option	Evidence tier (anti-aging endpoints)	Effect type	Time to outcome	Cost / month (US, 2026 est.)	Side effects	Reversibility	Who should consider	Who should skip
Caloric restriction / time-restricted eating	Tier 1 (geroscience literature; CALERIE trial; sustained CR in humans)	Multi-mechanism biological-aging signal modulation	12+ months for measurable biomarker shifts	$0 (saves money)	Risk of nutritional deficiency at extreme; muscle loss without resistance training	Reverses on stop	Almost everyone (modest CR or TRE); BMI > 22 strongly	Pregnancy, eating-disorder history, severe underweight, athlete with high energy needs
Resistance training + aerobic exercise	Tier 1 (largest mortality literature in medicine)	Multi-system: muscle/bone preservation, cardiovascular, cognitive, metabolic	8-16 weeks initial; lifetime compounding	$50-200	Soreness, injury risk if escalated too fast	None — habit	Almost everyone	No one
Sleep adequacy (7-9 hr, consistent schedule)	Tier 1	Multi-mechanism: cellular repair, HPA regulation, glymphatic clearance	2-6 weeks	$0-200	None	None	Everyone	No one
Mediterranean / lower-glycemic dietary pattern	Tier 1 (PREDIMED + cohort studies on mortality)	Cardiovascular, metabolic, neurodegenerative protection	6-24 months	$300-800 (food costs)	None at modest variation	None — habit	Anyone whose current dietary pattern is lower quality	No one
Sun protection + skin-aging prevention (retinoids, sunscreen)	Tier 1 (largest skin-aging literature)	Visible aging endpoints	16-26 weeks for retinoid effects	$30-150	Retinoid irritation; sunscreen cost; pregnancy considerations on tretinoin	Slow reversal on stop	Anyone wanting skin-aging mitigation	None — sun protection is non-optional
Metformin (off-label longevity)	Tier 1 for T2D/metabolic; Tier 2-3 for longevity in non-diabetic populations (TAME trial designed but not yet completed)	Glucose/insulin sensitivity; possibly autophagy + senescence	12-26 weeks for metabolic; longevity TBD	$10-30 (generic)	GI (manageable with titration); rare B12 deficiency on chronic; lactic acidosis in renal impairment	Reverses on stop	Pre-diabetic / metabolic-syndrome adjacent; longevity-curious adopters comfortable with off-label use	Athletes / high-performance training (acute lactate-handling concern); pregnancy; severe renal impairment
Rapamycin (off-label longevity)	Tier 1 mechanistic + animal lifespan studies; Tier 3 for humans (long-term safety in non-transplant populations not characterized)	mTORC1 inhibition; autophagy promotion; immune modulation	Long-term hypothesized; biomarker shifts variable	$50-300 with off-label prescription	Stomatitis, glucose intolerance, lipid elevation, immune modulation (variable infection risk)	Reverses on stop	Longevity-research-adjacent adopters; specific medical contexts; physician-managed	Active infections; surgery within 1 month; pregnancy; significant cardiovascular disease
NAD+ precursors (NR / NMN supplements)	Tier 2-3 (mechanistic plausibility; small RCT evidence on NAD levels; weak evidence on functional endpoints in humans)	Mitochondrial / sirtuin pathway support	12+ weeks	$40-120	Minimal at typical doses	Reverses on stop	Mechanistically-interested adopters comfortable with thin functional evidence	Anyone expecting dramatic / definitive effects
Glycine + NAC	Tier 2 (small but promising RCT evidence — Sekhar 2021 / 2022 series; biomarker improvements)	Glutathione synthesis; mitochondrial; cellular oxidative state	8-16 weeks	$15-40	GI at high doses	Reverses on stop	Older adults; adopters seeking inexpensive multi-mechanism support	None significant
Epitalon (subq, intermittent-cycle)	Tier 2 (Khavinson group Russian literature; small Western replication; in vitro telomerase evidence; animal mortality evidence)	Pineal-peptide signaling; theoretical telomerase activation; sleep/circadian	Within 1-2 weeks per cycle; long-term outcomes inferred	$30-60 per cycle	Mild — injection-site; sleep architecture changes	Low	Older adults interested in the Khavinson protocol; adopters comfortable with Russian-literature evidence	Anyone expecting Western RCT-grade certainty; active cancer; pregnancy
Thymosin alpha-1	Tier 1 for immune modulation in specific clinical contexts (HBV, HCV adjuvant); Tier 3-4 for anti-aging extrapolation	T-cell function, immune modulation	12+ weeks	$100-300 from prescription compounding	Mild; injection-site	Reverses on stop	Specific immunosenescence contexts; physician-managed for immune support in older adults	Standalone anti-aging tool — wrong frame
MOTS-c	Tier 2-3 (mitochondrial-derived peptide; small mechanistic + animal evidence)	Mitochondrial signaling; metabolic flexibility	Variable; minimal human characterization	$50-100 research suppliers	Minimal characterized	Reverses on stop	Frontier-bias adopters interested in the mitochondrial-aging axis	Anyone seeking established evidence-base; uncharacterized human safety
SS-31 / Elamipretide	Tier 1 for specific mitochondrial diseases (FDA fast track for primary mitochondrial myopathy); Tier 2-3 for anti-aging extrapolation	Cardiolipin stabilization; mitochondrial preservation	Variable	Variable (often very expensive in trial-context)	Minimal in published trials	Reverses on stop	Specific mitochondrial-disease patients (with prescription); research-adjacent adopters	Standalone consumer-anti-aging tool
Choosing acceptance / context check	Tier 1 in honesty	None	Immediate	$0	None	None	Anyone for whom "anti-aging" is partly cultural pressure rather than functional concern; anyone with low fitness who hasn't addressed lifestyle floor	Functional medical concerns (sarcopenia, cardiovascular disease, cognitive decline) require workup, not acceptance

The top four rows handle ~80% of biological-aging-relevant effect for most adults. The pharmacological geroscience options (metformin, rapamycin) are real interventions with growing evidence but appropriate medical context. The peptide options are mostly Tier 2-3 with variable evidence depth.

This guide carries the public comparison. The member continuation walks the Epitalon case in detail, the broader peptide-anti-aging evidence audit, and what an honest harm-reduction framework looks like.